BUZZ-Veracyte shares rise as data supports use of prostate cancer tests to guide treatment decisions

September 29 - ** Shares of diagnostic company Veracyte (VCYT.O) rose 1.6% in pre-market trading to $45.94

** The company stated that its Decipher test can identify intermediate-risk prostate cancer patients most likely to benefit from radiation therapy combined with hormone treatment

** Prostate cancer is cancer that occurs in the prostate gland; hormone therapy can lower the levels of hormones that promote tumor growth

** Veracyte said that for patients with intermediate/high Decipher scores, the risk of cancer metastasis within 10 years decreased by 8 percentage points after combined hormone therapy

** About 44% of patients had low scores and did not see significant benefit after the addition of hormone therapy

** The findings are based on a retrospective analysis of 395 patients from an advanced prostate cancer clinical trial

** As of the previous trading day’s close, the stock had declined about 23% year-to-date

(To assist non-English speakers, Reuters has automatically translated its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides it solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation functions.)